Profile data is unavailable for this security.
About the company
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
- Revenue in USD (TTM)1.44m
- Net income in USD-21.34m
- Incorporated2014
- Employees25.00
- LocationLongeveron Inc1951 NW 7th Ave, Ste 520MIAMI 33136United StatesUSA
- Phone+1 (305) 302-7158
- Fax+1 (302) 674-5266
- Websitehttps://www.longeveron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OSR Holdings Inc | 2.52m | -15.21m | 10.35m | -- | -- | 0.1161 | -- | 4.10 | -1.73 | -1.73 | 0.1939 | 3.46 | 0.0255 | -- | -- | -- | -22.03 | -- | -34.38 | -- | 18.35 | -- | -864.91 | -- | 0.2009 | -- | 0.0313 | -- | -- | -- | -697.08 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.75m | 44.00 | -- | 0.7349 | -- | 95.13 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 10.87m | 5.00 | -- | 0.5938 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 11.04m | 16.00 | -- | 0.9827 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Soligenix Inc | 0.00 | -11.46m | 11.50m | 14.00 | -- | 1.48 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.91m | 25.00 | -- | 1.18 | -- | 8.29 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 12.39m | 85.00 | -- | 2.64 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -34.45m | 12.52m | 1.00 | -- | 2.07 | -- | -- | -3.93 | -3.93 | 0.00 | 0.2266 | 0.00 | -- | -- | 0.00 | -459.62 | -172.68 | -1,377.41 | -460.87 | -- | -- | -- | -- | -- | -3,105.50 | 0.00 | -- | -- | -- | -161.73 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.82m | 82.00 | -- | 0.3684 | -- | 1.37 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 12.97m | -- | -- | 0.9074 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.00m | 1.00 | -- | 1.70 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 13.04m | 1.00 | -- | 0.4213 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 13.18m | 7.00 | 0.0584 | 2.59 | -- | 4.63 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 460.41k | 2.32% |
| Geode Capital Management LLCas of 31 Dec 2025 | 141.50k | 0.71% |
| UBS Securities LLCas of 31 Dec 2025 | 60.21k | 0.30% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 48.40k | 0.24% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 45.38k | 0.23% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 38.72k | 0.20% |
| XTX Markets LLCas of 31 Dec 2025 | 31.48k | 0.16% |
| Capital Investment Advisory Services LLCas of 31 Dec 2025 | 26.53k | 0.13% |
| Commonwealth Equity Services LLCas of 31 Dec 2025 | 25.16k | 0.13% |
| Hamilton Point Investment Advisors LLCas of 31 Dec 2025 | 22.45k | 0.11% |
